These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32332752)

  • 1. A vaccine-based nanosystem for initiating innate immunity and improving tumor immunotherapy.
    Zheng DW; Gao F; Cheng Q; Bao P; Dong X; Fan JX; Song W; Zeng X; Cheng SX; Zhang XZ
    Nat Commun; 2020 Apr; 11(1):1985. PubMed ID: 32332752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
    Fraillery D; Baud D; Pang SY; Schiller J; Bobst M; Zosso N; Ponci F; Nardelli-Haefliger D
    Clin Vaccine Immunol; 2007 Oct; 14(10):1285-95. PubMed ID: 17687110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
    Miyauchi S; Sanders PD; Guram K; Kim SS; Paolini F; Venuti A; Cohen EEW; Gutkind JS; Califano JA; Sharabi AB
    Cancer Res; 2020 Feb; 80(4):732-746. PubMed ID: 31848196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
    Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
    J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole recombinant Pichia pastoris expressing HPV16 L1 antigen is superior in inducing protection against tumor growth as compared to killed transgenic Leishmania.
    Bolhassani A; Muller M; Roohvand F; Motevalli F; Agi E; Shokri M; Rad MM; Hosseinzadeh S
    Hum Vaccin Immunother; 2014; 10(12):3499-508. PubMed ID: 25668661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine.
    Gu Y; Wei M; Wang D; Li Z; Xie M; Pan H; Wu T; Zhang J; Li S; Xia N
    Vaccine; 2017 Aug; 35(35 Pt B):4637-4645. PubMed ID: 28736197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
    Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
    Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
    Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors.
    Domingos-Pereira S; Galliverti G; Hanahan D; Nardelli-Haefliger D
    J Immunother Cancer; 2019 May; 7(1):122. PubMed ID: 31060612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationally designed peptide-conjugated gold/platinum nanosystem with active tumor-targeting for enhancing tumor photothermal-immunotherapy.
    Yang Q; Peng J; Shi K; Xiao Y; Liu Q; Han R; Wei X; Qian Z
    J Control Release; 2019 Aug; 308():29-43. PubMed ID: 31252039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant effect of docetaxel on HPV16 L2E6E7 fusion protein vaccine in a mouse model.
    Su X; Xu W; Guan R; Wang Y; Wu J; Zhai L; Chen G; Hu S
    Int Immunopharmacol; 2016 Sep; 38():16-25. PubMed ID: 27233002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens.
    Arribillaga L; Echeverria I; Belsue V; Gomez T; Lozano T; Casares N; Villanueva L; Domingos-Pereira S; Romero PJ; Nardelli-Haefliger D; Hervás-Stubbs S; Sarobe P; Rodriguez MJ; Carrascosa JL; Zürcher T; Lasarte JJ
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
    Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
    J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer.
    Sharma C; Dey B; Wahiduzzaman M; Singh N
    Vaccine; 2012 Aug; 30(36):5417-24. PubMed ID: 22717329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci.
    Bermúdez-Humarán LG; Cortes-Perez NG; Le Loir Y; Alcocer-González JM; Tamez-Guerra RS; de Oca-Luna RM; Langella P
    J Med Microbiol; 2004 May; 53(Pt 5):427-433. PubMed ID: 15096553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
    Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
    Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
    Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade.
    D'Alise AM; Leoni G; Cotugno G; Troise F; Langone F; Fichera I; De Lucia M; Avalle L; Vitale R; Leuzzi A; Bignone V; Di Matteo E; Tucci FG; Poli V; Lahm A; Catanese MT; Folgori A; Colloca S; Nicosia A; Scarselli E
    Nat Commun; 2019 Jun; 10(1):2688. PubMed ID: 31217437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
    Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
    Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.